DOCSLIB.ORG

2-Diss Preface1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2-Diss Preface1 Purification and preliminary characterization of Bothrops moojeni venom components active on haemostasis (Botmo Thesis) Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Anna Maria Perchu ć aus Warschau, Polen Referent: Prof. Dr. Beat Ernst Korreferent: Prof. Dr. phil. Jürg Meier Basel, 2010 Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Herrn Prof. Dr. Beat Ernst und Herrn Prof. Dr. phil. Jürg Meier Basel, den 16. September 2008 Prof. Dr. Eberhard Parlow Dekan Wissenschaft ist der gegenwärtige Stand unseres Irrtums Jakob Franz Kern (1897-1924) Anna Maria Perchuć – Botmo Thesis I Acknowledgements To my Doktorvater Prof. Dr. Beat Ernst for his patience, support and scientific advice. To Prof. Dr. phil. Jürg Meier (my Korreferent) and to Prof. Dr. Reto Brun for their input to my PhD exam. To Pentaphatm Ltd. for giving me the opportunity to work on the “Bothrops moojeni Venom Proteomics Project”. To Marianne and Bea for helpful discussions, scientific, practical and personal support, their enthusiasm and friendship. To Reto for giving me the encouragement and guidance and for coordinating the Botmo Project. To the whole Hämostase und Test-Kit-Entwicklung Team for their friendly and helpful cooperation. To Laure, Reto, Philou and the whole Atheris Team for their scientific assistance. To Marc and his Synthesis Team for their involvement in the Botmo Project, their help, support and sense of humour. To Uwe and Andre for the fruitful cooperation. To Andreas for his great assistance and many valuable suggestions. To Remo and Martin for their support in the cell culture lab. To Garth, Markus and Franco for reading the manuscript. To everyone else who gave me scientific guidance and helpful comments I offer my gratitude and thanks. You know who you are and so do I! On a personal level I must thank Bernadette and George for their superb support and the very special friendship, which I hope will last for long. II Anna Maria Perchuć – Botmo Thesis Also, my many dear Basler and Genfer Friends who gave me constant encouragement, real friendship and support. I must also acknowledge a particular debt of gratitude to my Sprüngli-Tante Danka (Ciotencja) and Bruno for their guidance and unfailing generosity. Finally, to my Parents and my Sister, I say with utmost sincerity ‘Thank you for making this possible!’. Anna Maria Perchuć – Botmo Thesis III Abstract For almost every factor involved in haemostasis there exists a venom protein that can mimic, activate or deactivate it. Many of these components are insensitive to the physiological and therapeutically used coagulation inhibitors and, because of their unique features, are applied as molecular tools for diagnosis and therapy of haemostatic disorders. Batroxobin, purified from the venoms of Bothrops moojeni and B. atrox snakes, commonly known under its trade names Reptilase® and Defibrase® is still widely used in pharmaceutical and diagnostic applications. However, the venom material needed for its production is not further analyzed, although it still contains a large number of potentially active compounds. The goal of this Botmo Thesis was the investigation of the crude B. moojeni venom for the identification of new active ingredients affecting haemostasis. Various protein purification methods, mass spectrometry and biocomputing, as well as newly developed coagulation screening tools were applied. B. moojeni crude venom and its fractions were used as model substances for the development of different screening tools applying mass spectrometry (MS) technology. The complexity of the venom provides a good selectivity assessment for the developed methods. By means of the novel MS approaches, 15 new sequences of Bradykinin-potentiating peptides (BPPs) were revealed, as well as the presence of acetylcholinesterase inhibiting venom component. To our knowledge, it is the first time acetylcholinesterase inhibiting properties were described in the venom of B. moojeni snake. Further, two novel Lys49 phospholipases A2 (PLA2) have been purified and fully sequenced, showing a characteristic sequence in the C-terminal region known in the literature to interact with heparin. Both PLA2s were able to interact in vitro with unfractionated heparin (UFH) and low molecular weight heparin (LMWH) neutralizing their anticoagulant properties. The revealed sequences, possessing the LMWH neutralization properties, may be of medical interest, because there is no LMWH antidote used in clinical applications. Moreover, a procoagulant protein resembling the coagulation FVIIa could be identified in the B. moojeni venom. Such activity has never been reported for any snake venom until now and further investigations would be of medical interest. IV Anna Maria Perchuć – Botmo Thesis In addition a new method was developed for the identification of active ingredients acting on blood platelets. It can be used for screening complex protein mixtures, such as B. moojeni venom, containing platelet activating prothrombin activators or thrombin like-enzymes. By means of this methodology, a platelet aggregation activator and platelet antagonist with broad inhibitory activity, which is most likely a disintegrin, could be identified. Up to now, it could be shown that B. moojeni venom is a highly complex mixture of active ingredients and still remains a huge “source of undiscovered potential”. Further purifications and characterization steps are needed in order to get a complete activity profile of the venom, also in fields other than haemostasis. Nevertheless, in the framework of this Botmo Thesis, some active ingredients, also such of medical interest, were identified. Anna Maria Perchuć – Botmo Thesis V Preface The work described in this thesis (Botmo Thesis) was conducted in the framework of “Bothrops moojeni venom proteomics” project under the supervision of Prof. Dr. Beat Ernst, Institute of Molecular Pharmacy at the University of Basel. It was performed at Pentapharm Ltd. in Aesch under the guidance of Dr. Marianne Wilmer and Dr. Reto Schöni. Parts of the Botmo Thesis have already been published in peer reviewed journals or will be submitted for publication. These manuscripts are presented in the corresponding paragraphs the way they were prepared for submission to the corresponding journals. The posters are included in Appendix. Manuscripts published or prepared: • Liesener A., Perchuc A.M., Schöni R., Wilmer M. and Karst U. “Screening for proteolytic activities in snake venom by means of a multiplexing electrospray ionization mass spectrometry assay scheme.” Rapid Commun Mass Spectrom. 2005; 19 (20): 2923-8. • Perchuc A.M., Menin L., Stöcklin R., Bühler B. and Schöni R. “The Potential of Bothrops moojeni Venom in the Field of Hemostasis. Established Use and New Insights.” Pathophysiol Haemost Thromb. 2005; 34: 241-245 • Liesener A., Perchuc A.M., Schöni R., Schebb N.H., Wilmer M. and Karst U. “Screening of acetylcholinesterase inhibitors in snake venom by electrospray mass spectrometry.” Pure Appl. Chem. 2007; 79: 2339-2349 • Menin L., Perchuc A.M., Favreau P., Perret F., Schöni R. and Stöcklin R. “Precursor ion mass spectra for efficient screening of Pyroglutamate and Bradykinin potentiating peptide (BPP)-type substances in Bothrops moojeni snake venom using liquid chromatography/tandem mass spectrometry.” Toxicon 2008 Jun 1; 51 (7): 1288-302 • Perchuc A.M., Menin L., Favreau P., Bühler B., Schöni R., Wilmer M. Ernst B. and Stöcklin R. “Isolation and characterization of two new Lys49 PLA2s with heparin neutralizing properties from Bothrops moojeni snake venom.” In preparation for Toxicon VI Anna Maria Perchuć – Botmo Thesis • Ritz V., Bühler B., Zaborosch Ch., Wilmer M., Ernst B. and Perchuc A.M. “A protease possessing blood coagulation factor VIIa-like activity isolated from venom of Bothrops moojeni snake.” In preparation for Thrombosis Research • Demler C., Bühler B., Menin L., Stöcklin R., Wilmer M., Ernst B. and Perchuc A.M. “Platelet-active substances in the venom of Bothrops moojeni snake – a novel evaluation method using whole blood aggregometry.“ In preparation for Platelets • Perchuc A.M. and Wilmer M. “Schlangengifte” in Hämostaseologie 2nd Edition In press Parts of this work were presented at conferences: Oral presentations: • Perchuc A.M., Menin L., Stöcklin R., Bühler B. and Schöni R. “The Potential of Bothrops moojeni Venom in the Field of Hemostasis. Established Use and New Insights.” 3rd International Conference on Exogenous Factors Affecting Thrombosis and Hemostasis (EFATH 2005); Sydney, Australia; August 13th- 14th, 2005 • Perchuc A.M., Menin L., Favreau P., Bühler B., Bulet P., Schöni R. and Stöcklin R. “Structural and heparin-binding properties of two Bothrops moojeni phospholipases A2 and their derived C-terminal synthetic fragments.” NP2D - Natural Peptides to Drug; Zermatt, Switzerland; April 18th-21st, 2006 • Perchuc A.M., Menin L., Favreau P., Bühler B., Bulet P., Schöni R. and Stöcklin R. “Heparin-neutralizing properties of two novel Lys49 PLA2 variants from the Bothrops moojeni venom.” 15th World Congress on Animal, Plant & Microbial Toxins; Glasgow, Scotland; July 23rd- 28th, 2006 Posters: • Perchuc A.M., Menin L., Stöcklin R., Bühler B. and Schöni R. “Bothrops moojeni Proteomics – A Second Look at the Venom.” 15th European Symposium on Animal, Plant and Microbial Toxins; Brdo Estate (Kranj), Slovenia; June 19th- 23rd, 2004 Anna Maria Perchuć – Botmo Thesis
Load more

Recommended publications
  • Urokinase, a Promising Candidate for Fibrinolytic Therapy for Intracerebral Hemorrhage
    LABORATORY INVESTIGATION J Neurosurg 126:548–557, 2017 Urokinase, a promising candidate for fibrinolytic therapy for intracerebral hemorrhage *Qiang Tan, MD,1 Qianwei Chen, MD1 Yin Niu, MD,1 Zhou Feng, MD,1 Lin Li, MD,1 Yihao Tao, MD,1 Jun Tang, MD,1 Liming Yang, MD,1 Jing Guo, MD,2 Hua Feng, MD, PhD,1 Gang Zhu, MD, PhD,1 and Zhi Chen, MD, PhD1 1Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing; and 2Department of Neurosurgery, 211st Hospital of PLA, Harbin, People’s Republic of China OBJECTIVE Intracerebral hemorrhage (ICH) is associated with a high rate of mortality and severe disability, while fi- brinolysis for ICH evacuation is a possible treatment. However, reported adverse effects can counteract the benefits of fibrinolysis and limit the use of tissue-type plasminogen activator (tPA). Identifying appropriate fibrinolytics is still needed. Therefore, the authors here compared the use of urokinase-type plasminogen activator (uPA), an alternate thrombolytic, with that of tPA in a preclinical study. METHODS Intracerebral hemorrhage was induced in adult male Sprague-Dawley rats by injecting autologous blood into the caudate, followed by intraclot fibrinolysis without drainage. Rats were randomized to receive uPA, tPA, or saline within the clot. Hematoma and perihematomal edema, brain water content, Evans blue fluorescence and neurological scores, matrix metalloproteinases (MMPs), MMP mRNA, blood-brain barrier (BBB) tight junction proteins, and nuclear factor–κB (NF-κB) activation were measured to evaluate the effects of these 2 drugs in ICH. RESULTS In comparison with tPA, uPA better ameliorated brain edema and promoted an improved outcome after ICH.
    [Show full text]
  • Replacing the First Epidermal Growth Factor-Like Domain of Factor IX with That of Factor VII Enhances Activity in Vitro and in Canine Hemophilia B
    Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B. J Y Chang, … , K M Brinkhous, H R Roberts J Clin Invest. 1997;100(4):886-892. https://doi.org/10.1172/JCI119604. Research Article Using the techniques of molecular biology, we made a chimeric Factor IX by replacing the first epidermal growth factor- like domain with that of Factor VII. The resulting recombinant chimeric molecule, Factor IXVIIEGF1, had at least a twofold increase in functional activity in the one-stage clotting assay when compared to recombinant wild-type Factor IX. The increased activity was not due to contamination with activated Factor IX, nor was it due to an increased rate of activation by Factor VIIa-tissue factor or by Factor XIa. Rather, the increased activity was due to a higher affinity of Factor IXVIIEGF1 for Factor VIIIa with a Kd for Factor VIIIa about one order of magnitude lower than that of recombinant wild- type Factor IXa. In addition, results from animal studies show that this chimeric Factor IX, when infused into a dog with hemophilia B, exhibits a greater than threefold increase in clotting activity, and has a biological half-life equivalent to recombinant wild-type Factor IX. Find the latest version: https://jci.me/119604/pdf Replacing the First Epidermal Growth Factor-like Domain of Factor IX with That of Factor VII Enhances Activity In Vitro and in Canine Hemophilia B Jen-Yea Chang,* Dougald M. Monroe,* Darrel W. Stafford,*‡ Kenneth M.
    [Show full text]
  • Therapeutic Fibrinolysis How Efficacy and Safety Can Be Improved
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL.68,NO.19,2016 ª 2016 PUBLISHED BY ELSEVIER ON BEHALF OF THE ISSN 0735-1097/$36.00 AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION http://dx.doi.org/10.1016/j.jacc.2016.07.780 THE PRESENT AND FUTURE REVIEW TOPIC OF THE WEEK Therapeutic Fibrinolysis How Efficacy and Safety Can Be Improved Victor Gurewich, MD ABSTRACT Therapeutic fibrinolysis has been dominated by the experience with tissue-type plasminogen activator (t-PA), which proved little better than streptokinase in acute myocardial infarction. In contrast, endogenous fibrinolysis, using one-thousandth of the t-PA concentration, is regularly lysing fibrin and induced Thrombolysis In Myocardial Infarction flow grade 3 patency in 15% of patients with acute myocardial infarction. This efficacy is due to the effects of t-PA and urokinase plasminogen activator (uPA). They are complementary in fibrinolysis so that in combination, their effect is synergistic. Lysis of intact fibrin is initiated by t-PA, and uPA activates the remaining plasminogens. Knockout of the uPA gene, but not the t-PA gene, inhibited fibrinolysis. In the clinic, a minibolus of t-PA followed by an infusion of uPA was administered to 101 patients with acute myocardial infarction; superior infarct artery patency, no reocclusions, and 1% mortality resulted. Endogenous fibrinolysis may provide a paradigm that is relevant for therapeutic fibrinolysis. (J Am Coll Cardiol 2016;68:2099–106) © 2016 Published by Elsevier on behalf of the American College of Cardiology Foundation. n occlusive intravascular thrombus triggers fibrinolysis, as shown by it frequently not being A the cardiovascular diseases that are the lead- identified specifically in publications on clinical ing causes of death and disability worldwide.
    [Show full text]
  • Manual D'estil Per a Les Ciències De Laboratori Clínic
    MANUAL D’ESTIL PER A LES CIÈNCIES DE LABORATORI CLÍNIC Segona edició Preparada per: XAVIER FUENTES I ARDERIU JAUME MIRÓ I BALAGUÉ JOAN NICOLAU I COSTA Barcelona, 14 d’octubre de 2011 1 Índex Pròleg Introducció 1 Criteris generals de redacció 1.1 Llenguatge no discriminatori per raó de sexe 1.2 Llenguatge no discriminatori per raó de titulació o d’àmbit professional 1.3 Llenguatge no discriminatori per raó d'ètnia 2 Criteris gramaticals 2.1 Criteris sintàctics 2.1.1 Les conjuncions 2.2 Criteris morfològics 2.2.1 Els articles 2.2.2 Els pronoms 2.2.3 Els noms comuns 2.2.4 Els noms propis 2.2.4.1 Els antropònims 2.2.4.2 Els noms de les espècies biològiques 2.2.4.3 Els topònims 2.2.4.4 Les marques registrades i els noms comercials 2.2.5 Els adjectius 2.2.6 El nombre 2.2.7 El gènere 2.2.8 Els verbs 2.2.8.1 Les formes perifràstiques 2.2.8.2 L’ús dels infinitius ser i ésser 2.2.8.3 Els verbs fer, realitzar i efectuar 2.2.8.4 Les formes i l’ús del gerundi 2.2.8.5 L'ús del verb haver 2.2.8.6 Els verbs haver i caldre 2.2.8.7 La forma es i se davant dels verbs 2.2.9 Els adverbis 2.2.10 Les locucions 2.2.11 Les preposicions 2.2.12 Els prefixos 2.2.13 Els sufixos 2.2.14 Els signes de puntuació i altres signes ortogràfics auxiliars 2.2.14.1 La coma 2.2.14.2 El punt i coma 2.2.14.3 El punt 2.2.14.4 Els dos punts 2.2.14.5 Els punts suspensius 2.2.14.6 El guionet 2.2.14.7 El guió 2.2.14.8 El punt i guió 2.2.14.9 L’apòstrof 2.2.14.10 L’interrogant 2 2.2.14.11 L’exclamació 2.2.14.12 Les cometes 2.2.14.13 Els parèntesis 2.2.14.14 Els claudàtors 2.2.14.15
    [Show full text]
  • The Molecular Basis of Blood Coagulation Review
    Cell, Vol. 53, 505-518, May 20, 1988, Copyright 0 1988 by Cell Press The Molecular Basis Review of Blood Coagulation Bruce Furie and Barbara C. Furie into the fibrin polymer. The clot, formed after tissue injury, Center for Hemostasis and Thrombosis Research is composed of activated platelets and fibrin. The clot Division of Hematology/Oncology mechanically impedes the flow of blood from the injured Departments of Medicine and Biochemistry vessel and minimizes blood loss from the wound. Once a New England Medical Center stable clot has formed, wound healing ensues. The clot is and Tufts University School of Medicine gradually dissolved by enzymes of the fibrinolytic system. Boston, Massachusetts 02111 Blood coagulation may be initiated through either the in- trinsic pathway, where all of the protein components are present in blood, or the extrinsic pathway, where the cell- Overview membrane protein tissue factor plays a critical role. Initia- tion of the intrinsic pathway of blood coagulation involves Blood coagulation is a host defense system that assists in the activation of factor XII to factor Xlla (see Figure lA), maintaining the integrity of the closed, high-pressure a reaction that is promoted by certain surfaces such as mammalian circulatory system after blood vessel injury. glass or collagen. Although kallikrein is capable of factor After initiation of clotting, the sequential activation of cer- XII activation, the particular protease involved in factor XII tain plasma proenzymes to their enzyme forms proceeds activation physiologically is unknown. The collagen that through either the intrinsic or extrinsic pathway of blood becomes exposed in the subendothelium after vessel coagulation (Figure 1A) (Davie and Fiatnoff, 1964; Mac- damage may provide the negatively charged surface re- Farlane, 1964).
    [Show full text]
  • Mechanism of Ancrod Anticoagulation: a Direct Proteolytic Effect on Fibrin
    Mechanism of ancrod anticoagulation: A direct proteolytic effect on fibrin Salvatore V. Pizzo, … , Robert L. Hill, Patrick A. McKee J Clin Invest. 1972;51(11):2841-2850. https://doi.org/10.1172/JCI107107. Fibrin formed in response to ancrod, reptilase, or thrombin was reduced by β-mercaptoethanol and examined by sodium dodecyl sulfate polyacrylamide gel electrophoresis. It was found that ancrod progressively and totally digested the α- chains of fibrin monomers at sites different than plasmin; however, further digestion of fibrin monomers by either reptilase or thrombin was not observed. Highly purified ancrod did not activate fibrin-stabilizing factor (FSF); however, the reptilase preparation used in these experiments, like thrombin, activated FSF and thereby promoted cross-link formation. Fibrin, formed by clotting purified human fibrinogen with ancrod, reptilase, or thrombin for increasing periods of time in the presence of plasminogen, was incubated with urokinase and observed for complete lysis. Fibrin formed by ancrod was strikingly more vulnerable to plasmin digestion than was fibrin formed by reptilase or thrombin. The lysis times for fibrin formed for 2 hr by ancrod, reptilase, or thrombin were 18, 89, and 120 min, respectively. Evidence was also obtained that neither ancrod nor reptilase activated human plasminogen. These results indicate that fibrin formed by ancrod is not cross-linked and has significantly degraded α-chains: as expected, ancrod-formed fibrin is markedly susceptible to digestion by plasmin. Find the latest version: https://jci.me/107107/pdf Mechanism of Ancrod Anticoagulation A DIRECT PROTEOLYTIC EFFECT ON FIBRIN SALVATORE V. PIZZO, MARTIN L. SCHWARTZ, ROBERT L. HILL, and PATRICK A.
    [Show full text]
  • Bioengineering Coagulation Factor Xa Substrate Specificity Into
    Bioengineering Coagulation Factor Xa Substrate Specificity into Streptomyces griseus Trypsin by > Michael J. Page B.Sc, Carleton University, 1998 A THESIS SUBMITTED IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY in THE FACULTY OF GRADUATE STUDIES Department of Biochemistry and Molecular Biology We accept this thesis as conforming to the required standard THE UNIVERSITY OF BRITISH COLUMBIA April 2004 © Michael J. Page, 2004 Abstract Extended substrate specificity is exhibited by a number of highly evolved members of the SI peptidase family, such as the vertebrate blood coagulation proteases. Dissection of this substrate specificity has been hindered by the complexity and physiological requirements of these proteases. In order to understand the mechanisms of extended substrate specificity, a bacterial trypsin-like enzyme, Streptomyces griseus trypsin (SGT), was chosen as a scaffold for the introduction of extended substrate specificity through structure-based genetic engineering. Recombinant and mutant SGT proteases were produced in a B. subtilis expression system, which constitutively secretes active protease into the extracellular medium at greater than 15 mg/L of culture. Comparison of the recombinant wild-type protease to the natively produced enzyme demonstrated near identity in enzymatic and structural properties. To begin construction of a high specificity protease, four mutants in the S1 substrate binding pocket (T190A, T190S, T190V, and T190P) were produced and examined for differences in the Arg:Lys preference. Only the T190P mutant of SGT demonstrated a significant increase in PI arginine to lysine preference - a three-fold improvement to 16:1 - with only a minor reduction in catalytic activity (kcat reduction of 25%).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan Et Al
    US 2004.008 1648A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan et al. (43) Pub. Date: Apr. 29, 2004 (54) ADZYMES AND USES THEREOF Publication Classification (76) Inventors: Noubar B. Afeyan, Lexington, MA (51) Int. Cl." ............................. A61K 38/48; C12N 9/64 (US); Frank D. Lee, Chestnut Hill, MA (52) U.S. Cl. ......................................... 424/94.63; 435/226 (US); Gordon G. Wong, Brookline, MA (US); Ruchira Das Gupta, Auburndale, MA (US); Brian Baynes, (57) ABSTRACT Somerville, MA (US) Disclosed is a family of novel protein constructs, useful as Correspondence Address: drugs and for other purposes, termed “adzymes, comprising ROPES & GRAY LLP an address moiety and a catalytic domain. In Some types of disclosed adzymes, the address binds with a binding site on ONE INTERNATIONAL PLACE or in functional proximity to a targeted biomolecule, e.g., an BOSTON, MA 02110-2624 (US) extracellular targeted biomolecule, and is disposed adjacent (21) Appl. No.: 10/650,592 the catalytic domain So that its affinity Serves to confer a new Specificity to the catalytic domain by increasing the effective (22) Filed: Aug. 27, 2003 local concentration of the target in the vicinity of the catalytic domain. The present invention also provides phar Related U.S. Application Data maceutical compositions comprising these adzymes, meth ods of making adzymes, DNA's encoding adzymes or parts (60) Provisional application No. 60/406,517, filed on Aug. thereof, and methods of using adzymes, Such as for treating 27, 2002. Provisional application No. 60/423,754, human Subjects Suffering from a disease, Such as a disease filed on Nov.
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,561,811 B2 Bluchel Et Al
    USOO8561811 B2 (12) United States Patent (10) Patent No.: US 8,561,811 B2 Bluchel et al. (45) Date of Patent: Oct. 22, 2013 (54) SUBSTRATE FOR IMMOBILIZING (56) References Cited FUNCTIONAL SUBSTANCES AND METHOD FOR PREPARING THE SAME U.S. PATENT DOCUMENTS 3,952,053 A 4, 1976 Brown, Jr. et al. (71) Applicants: Christian Gert Bluchel, Singapore 4.415,663 A 1 1/1983 Symon et al. (SG); Yanmei Wang, Singapore (SG) 4,576,928 A 3, 1986 Tani et al. 4.915,839 A 4, 1990 Marinaccio et al. (72) Inventors: Christian Gert Bluchel, Singapore 6,946,527 B2 9, 2005 Lemke et al. (SG); Yanmei Wang, Singapore (SG) FOREIGN PATENT DOCUMENTS (73) Assignee: Temasek Polytechnic, Singapore (SG) CN 101596422 A 12/2009 JP 2253813 A 10, 1990 (*) Notice: Subject to any disclaimer, the term of this JP 2258006 A 10, 1990 patent is extended or adjusted under 35 WO O2O2585 A2 1, 2002 U.S.C. 154(b) by 0 days. OTHER PUBLICATIONS (21) Appl. No.: 13/837,254 Inaternational Search Report for PCT/SG2011/000069 mailing date (22) Filed: Mar 15, 2013 of Apr. 12, 2011. Suen, Shing-Yi, et al. “Comparison of Ligand Density and Protein (65) Prior Publication Data Adsorption on Dye Affinity Membranes Using Difference Spacer Arms'. Separation Science and Technology, 35:1 (2000), pp. 69-87. US 2013/0210111A1 Aug. 15, 2013 Related U.S. Application Data Primary Examiner — Chester Barry (62) Division of application No. 13/580,055, filed as (74) Attorney, Agent, or Firm — Cantor Colburn LLP application No.
    [Show full text]
  • Evaluation of the Efficacy of Three Plant Extracts Against Venoms of Five Snake Species in Northern Nigeria
    EVALUATION OF THE EFFICACY OF THREE PLANT EXTRACTS AGAINST VENOMS OF FIVE SNAKE SPECIES IN NORTHERN NIGERIA BY YUNUSA YAHAYA DEPARTMENT OF VETERINARY PUBLIC HEALTH AND PREVENTIVE MEDICINE FACULTY OF VETERINARY MEDICINE AHMADU BELLO UNIVERSITY, ZARIA MARCH 2017 EVALUATION OF THE EFFICACY OF THREE PLANT EXTRACTS AGAINST VENOMS OF FIVE SNAKE SPECIES IN NORTHERN NIGERIA BY YUNUSA Yahaya P15VTPH9009 BSc, (1997), MSc (2006) (ABU, ZARIA) A THESIS SUBMITTED TO THE SCHOOL OF POSTGRADUATE STUDIES, AHMADU BELLO UNIVERSITY, ZARIA IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE AWARD OF DEGREE OF DOCTOR OF PHILOSOPHY IN VETERINARY PUBLIC HEALTH AND PREVENTIVE MEDICINE DEPARTMENT OF VETERINARY PUBLIC HEALTH AND PREVENTIVE MEDICINE, AHMADU BELLO UNIVERSITY, ZARIA March, 2017 i DECLARATION I declare that the work in this thesis entitled “Evaluation of the efficacy of three plant extracts against venoms of five snake species in Northern Nigeria” has been performed by me in the Department of Veterinary Public Health and Preventive Medicine. The information derived from the literature has been duly acknowledged in the text and list of references provided. No part of this dissertation was previously presented for another degree or diploma at this or any other Institution. _____________________ ___________________ ______________ YUNUSA Yahaya Signature Date ii CERTIFICATION The thesis entitled “Evaluation of the efficacy of three plant extracts against venoms of five snake species in Northern Nigeria” by YUNUSA Yahaya meets the regulations governing the award of Doctor of philosophy degree in Veterinary Public Health and Preventive Medicine of Ahmadu Bello University, Zaria and is approved for its contribution to knowledge and literary presentation.
    [Show full text]
  • Enhancement of the Expression of Urokinase-Type Plasminogen Activator from PC-3 Human Prostate Cancer Cells by Thrombin'
    ICANCERRESEARCH54,3300-3304,June15,1@94I Enhancement of the Expression of Urokinase-Type Plasminogen Activator from PC-3 Human Prostate Cancer Cells by Thrombin' Etsuo Yoshida,2 Elaine N. Verrusio, Hisashi Mihara,2 Doyeun Oh, and Hau C. Kwaan3 Department of Medicine, Hematology/Oncology Division, Northwestern University Medical Schoo4 and VA Lakeside Medical Ce,Uer, Chicago, Illinois 6@11 [E. V., E. N. V., D. 0., H. C. K./, and Department ofPhysiology, Miyazaki Medical College, Miyazaki 889-16, Japan [H. M.J ABSTRACT extracellular matrix. This is supported by the fact that anti-uPA could reduce tumor invasion and metastatic ability (7). uPA has been also The presence of procoagulants and fibrin deposition have been dem found to have a mitogenic effect on several cell lines (8, 9). onstrated in malignant tumors. Although thrombin, a key enzyme in In view of these findings, it is possible that thrombin may affect coagulation, has other various biological functions, the significance of its tumor cell behavior by modulating the expression of the components presence in tumors is not known. We studied the effects of thrombin on of the plasminogen-plasmin system. In the present study, we focused the expression of urokinase-type plasminogen activator (uPA) which is on the effect of thrombin on uPA expression in cancer cells and known to play a role in tumor invasion, using a human prostate cancer cell line PC-3. Human a-thrombin added to cultures of PC-3 produced a examined three prostate cancer cell lines: PC-3, a high uPA producer; dose-dependent and time-dependent increased secretion of uPA that was DU-145, which is a low uPA producer; and LNCaP, a non-uPA greatest at 3—6h after exposure to thrombin.
    [Show full text]